

1. Nasser, Y., Bashashati, M. & Andrews, C. N. Toward modulation of the endocannabinoid system for treatment of gastrointestinal disease: FAAHster but not “higher”. *Neurogastroenterol Motil* **26**, 447-454 (2014).
2. Lomazzo, E. et al. Therapeutic Potential of Inhibitors of Endocannabinoid Degradation for the Treatment of Stress-Related Hyperalgesia in an Animal Model of Chronic Pain. *Neuropsychopharmacology* (2014).
3. Soria-Gomez, E. et al. The endocannabinoid system controls food intake via olfactory processes. *Nat Neurosci* **17**, 407-415 (2014).
4. Burokas, A. et al. Relationships between serotonergic and cannabinoid system in depressive-like behavior: a PET study with [11C]-DASB. *J Neurochem* (2014).
5. Zoppi, S. et al. Regulatory role of the Cannabinoid-2 receptor in stress-induced neuroinflammation in mice. *Br J Pharmacol* (2014).
6. Molina, P. E. et al. Modulation of Gut-Specific Mechanisms by Chronic Delta-Tetrahydrocannabinol Administration in Male Rhesus Macaques Infected with Simian Immunodeficiency Virus: A Systems Biology Analysis. *AIDS Res Hum Retroviruses* (2014).
7. Liu, B., Song, S., Jones, P. M. & Persaud, S. J. GPR55: From orphan to metabolic regulator? *Pharmacol Ther* (2014).
8. Soria-Gomez, E. et al. Cannabinoid type-1 receptors in the paraventricular nucleus of the hypothalamus inhibit stimulated food intake. *Neuroscience* **263**, 46-53 (2014).
9. Hiebel, C., Kromm, T., Stark, M. & Behl, C. Cannabinoid receptor 1 modulates the autophagic flux independent of mTOR- and BECLIN1-complex. *J Neurochem* (2014).
10. Hebert-Chatelain, E. et al. Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor. *Mol Metab* **3**, 495-504 (2014).
11. Chiarlone, A. et al. A restricted population of CB1 cannabinoid receptors with neuroprotective activity. *Proc Natl Acad Sci U S A* **111**, 8257-8262 (2014).
12. Gutierrez-Valdez, A. L. et al. The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson’s disease and L-DOPA-induced dyskinesia. *Behav Pharmacol* **24**, 640-652 (2013).
13. Campos, A. C. et al. The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. *Int J Neuropsychopharmacol* 1-13 (2013).
14. Steindel, F. et al. Neuron-type specific cannabinoid-mediated G protein signalling in mouse hippocampus. *J Neurochem* (2013).
15. Fagundo, A. B. et al. Modulation of the Endocannabinoids N-Arachidonylethanolamine (AEA) and 2-Arachidonoylglycerol (2-AG) on Executive Functions in Humans. *PLoS One* **8**, e66387 (2013).
16. Kianian, M., Al-Banna, N. A., Kelly, M. E. & Lehmann, C. Inhibition of endocannabinoid degradation in experimental endotoxemia reduces leukocyte adhesion and improves capillary perfusion in the gut. *J Basic Clin Physiol Pharmacol* **24**, 27-33 (2013).

17. Lim, C. T. et al. Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism. *Mol Cell Endocrinol* **365**, 303-308 (2013).
18. Dipatrizio, N. V., Joslin, A., Jung, K. M. & Piomelli, D. Endocannabinoid signaling in the gut mediates preference for dietary unsaturated fats. *FASEB J* (2013).
19. Soderstrom, K. & Wilson, A. R. Developmental pattern of diacylglycerol lipase-alpha (DAGLalpha) immunoreactivity in brain regions important for song learning and control in the zebra finch (*Taeniopygia guttata*). *J Chem Neuroanat* (2013).
20. Ruehle, S. et al. Cannabinoid CB1 Receptor in Dorsal Telencephalic Glutamatergic Neurons: Distinctive Sufficiency for Hippocampus-Dependent and Amygdala-Dependent Synaptic and Behavioral Functions. *J Neurosci* **33**, 10264-10277 (2013).
21. Sarro-Ramirez, A. et al. Brain molecules and appetite: The case of oleoylethanolamide. *Cent Nerv Syst Agents Med Chem* (2013).
22. Battista, N. et al. Altered expression of type-1 and type-2 cannabinoid receptors in celiac disease. *PLoS One* **8**, e62078 (2013).
23. Li, K. et al. A role for O-1602 and G protein-coupled receptor GPR55 in the control of colonic motility in mice. *Neuropharmacology* (2013).
24. Alhouayek, M. & Muccioli, G. G. The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. *Trends Mol Med* (2012).
25. Jones, R. B., Dockray, G. J. & Thompson, D. G. The effects of fasting duration on gastric emptying in man, an exploration of the role of the endocannabinoid system and inter-individual responsiveness. *Neurogastroenterol Motil* (2012).
26. Diaz-Alonso, J. et al. The CB1 Cannabinoid Receptor Drives Corticospinal Motor Neuron Differentiation through the Ctip2/Satb2 Transcriptional Regulation Axis. *J Neurosci* **32**, 16651-16665 (2012).
27. Wong, B. S. et al. Randomized pharmacodynamic and pharmacogenetic trial of dronabinol effects on colon transit in irritable bowel syndrome-diarrhea. *Neurogastroenterol Motil* (2012).
28. Romero-Zerbo, S. Y. et al. Overexpression of cannabinoid CB2 receptor in the brain induces hyperglycaemia and a lean phenotype in adult mice. *J Neuroendocrinol* (2012).
29. Haring, M., Guggenhuber, S. & Lutz, B. Neuronal populations mediating the effects of endocannabinoids on stress and emotionality. *Neuroscience* (2012).
30. Benard, G. et al. Mitochondrial CB(1) receptors regulate neuronal energy metabolism. *Nat Neurosci* (2012).
31. Izzo, A. A. et al. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from *Cannabis sativa*, on inflammation-induced hypermotility in mice. *Br J Pharmacol* (2012).
32. Cardinal, P. et al. Hypothalamic CB1 Cannabinoid Receptors Regulate Energy Balance in Mice. *Endocrinology* (2012).
33. Chang, C. E., Ai, R., Gutierrez, M. & Marsella, M. J. Homology modeling of cannabinoid receptors: discovery of cannabinoid analogues for therapeutic use. *Methods Mol Biol* **819**, 595-613 (2012).
34. Ross, G. R., Lichtman, A., Dewey, W. L. & Akbarali, H. I. Evidence for the Putative Cannabinoid Receptor (GPR55)-Mediated Inhibitory Effects on Intestinal Contractility in Mice. *Pharmacology* **90**, 55-65 (2012).

35. Kim, D. K. et al. Estrogen-related receptor gamma controls hepatic CB1 receptor-mediated CYP2E1 expression and oxidative liver injury by alcohol. *Gut* (2012).
36. Arevalo-Martin, A. et al. Early Endogenous Activation of CB1 and CB2 Receptors after Spinal Cord Injury Is a Protective Response Involved in Spontaneous Recovery. *PLoS One* **7**, e49057 (2012).
37. Sykaras, A. G., Demenis, C., Case, R. M., McLaughlin, J. T. & Smith, C. P. Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and Fatty Acid receptors. *PLoS One* **7**, e42373 (2012).
38. Haring, M., Grieb, M., Monory, K., Lutz, B. & Moreira, F. A. Cannabinoid CB(1) receptor in the modulation of stress coping behavior in mice: The role of serotonin and different forebrain neuronal subpopulations. *Neuropharmacology* (2012).
39. Esposito, G. et al. Cannabidiol in Inflammatory Bowel Diseases: A Brief Overview. *Phytother Res* (2012).
40. Schicho, R. & Storr, M. A potential role for GPR55 in gastrointestinal functions. *Curr Opin Pharmacol* (2012).
41. Wang, L., Yang, T., Qian, W. & Hou, X. The role of endocannabinoids in visceral hyposensitivity induced by rapid eye movement sleep deprivation in rats: regional differences. *Int J Mol Med* **27**, 119-126 (2011).
42. Di Sabatino, A. et al. The endogenous cannabinoid system in the gut of patients with inflammatory bowel disease. *Mucosal Immunol* (2011).
43. Ruehle, S., Aparisi Rey, A., Remmers, F. & Lutz, B. The endocannabinoid system in anxiety, fear memory and habituation. *J Psychopharmacol* (2011).
44. Wellner, N. et al. Studies on the anorectic effect of N-acylphosphatidylethanolamine and phosphatidylethanolamine in mice. *Biochim Biophys Acta* **1811**, 508-512 (2011).
45. Cisneros, J. A. et al. Structure-Activity Relationship of a New Series of Reversible Dual Monoacylglycerol Lipase / Fatty Acid Amide Hydrolase Inhibitors. *J Med Chem* (2011).
46. Zoerner, A. A. et al. Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: Minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. *J Chromatogr B Analyt Technol Biomed Life Sci* (2011).
47. Zoerner, A. A. et al. Quantification of endocannabinoids in biological systems by chromatography and mass spectrometry: A comprehensive review from an analytical and biological perspective. *Biochim Biophys Acta* (2011).
48. Verhoeckx, K. C. et al. Presence, formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. *Biochim Biophys Acta* (2011).
49. Vinod, K. Y. et al. Innate difference in the endocannabinoid signaling and its modulation by alcohol consumption in alcohol-preferring sP rats. *Addict Biol* (2011).
50. Bashashati, M. et al. INHIBITING FATTY ACID AMIDE HYDROLASE NORMALIZES ENDOTOXIN-INDUCED ENHANCED GASTROINTESTINAL MOTILITY IN THE MOUSE. *Br J Pharmacol* (2011).
51. Di Marzo, V. & Piscitelli, F. Gut feelings about the endocannabinoid system.

- Neurogastroenterol Motil* **23**, 391-398 (2011).
52. Cuellar, J. N. & Isokawa, M. Ghrelin-induced activation of cAMP signal transduction and its negative regulation by endocannabinoids in the hippocampus. *Neuropharmacology* **60**, 842-851 (2011).
 53. Marco, E. M. et al. Endocannabinoid system and psychiatry: in search of a neurobiological basis for detrimental and potential therapeutic effects. *Front Behav Neurosci* **5**, 63 (2011).
 54. Nomura, D. K. et al. Endocannabinoid Hydrolysis Generates Brain Prostaglandins That Promote Neuroinflammation. *Science* (2011).
 55. Marrs, W. R. et al. Dual inhibition of alpha/beta hydrolase domain 6 and fatty acid amide hydrolase increases endocannabinoid levels in neurons. *J Biol Chem* (2011).
 56. Martin-Couce, L., Martin-Fontecha, M., Capolicchio, S., Lopez-Rodriguez, M. L. & Ortega-Gutierrez, S. Development of Endocannabinoid-Based Chemical Probes for the Study of Cannabinoid Receptors. *J Med Chem* (2011).
 57. Haring, M., Kaiser, N., Monory, K. & Lutz, B. Circuit Specific Functions of Cannabinoid CB1 Receptor in the Balance of Investigatory Drive and Exploration. *PLoS One* **6**, e26617 (2011).
 58. Gutierrez, M. et al. Cannabinomimetic lipid from a marine cyanobacterium. *J Nat Prod* **74**, 2313-2317 (2011).
 59. De Filippis, D. et al. Cannabidiol reduces intestinal inflammation through the control of neuroimmune axis. *PLoS One* **6**, e28159 (2011).
 60. Schicho, R. & Storr, M. Alternative targets within the endocannabinoid system for future treatment of gastrointestinal diseases. *Can J Gastroenterol* **25**, 377-383 (2011).
 61. Lin, X. H. et al. A novel CB receptor GPR55 and its ligands are involved in regulation of gut movement in rodents. *Neurogastroenterol Motil* (2011).
 62. Breunig, E. et al. The Endocannabinoid 2-Arachidonoyl-Glycerol Controls Odor Sensitivity in Larvae of *Xenopus laevis*. *J Neurosci* **30**, 8965-8973 (2010).
 63. Gomez, O. et al. The constitutive production of the endocannabinoid 2-arachidonoylglycerol participates in oligodendrocyte differentiation. *Glia* (2010).
 64. Alvaro-Bartolome, M. et al. Regulation of Fas receptor/Fas-associated protein with death domain apoptotic complex and associated signalling systems by cannabinoid receptors in the mouse brain. *Br J Pharmacol* **160**, 643-656 (2010).
 65. Dockray, G. J. & Burdyga, G. Plasticity in vagal afferent neurons during feeding and fasting: mechanisms and significance. *Acta Physiol (Oxf)* (2010).
 66. Cluny, N. L. et al. Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone (SAB378), a peripherally restricted, cannabinoid CB1/CB2 receptor agonist inhibits gastrointestinal motility, but has no effect on experimental colitis in mice. *J Pharmacol Exp Ther* (2010).
 67. Gutierrez-Lopez, M. D. et al. Involvement of 2-arachidonoyl glycerol in the increased consumption of and preference for ethanol of mice treated with neurotoxic doses of methamphetamine. *Br J Pharmacol* **160**, 772-783 (2010).
 68. Burdyga, G., Varro, A., Dimaline, R., Thompson, D. G. & Dockray, G. J. Expression of cannabinoid CB1 receptors by vagal afferent neurons: kinetics, and role in influencing neurochemical phenotype. *Am J Physiol Gastrointest Liver Physiol* (2010).

69. Rohrich, J., Zorzntlein, S., Becker, J. & Urban, R. Detection of Delta9-tetrahydrocannabinol and amphetamine-type stimulants in oral fluid using the Rapid Stat point-of-collection drug-testing device. *J Anal Toxicol* **34**, 155-161 (2010).
70. Uriguen, L., Garcia-Gutierrez, M. S. & Manzanares, J. Decreased GABAA and GABAB receptor functional activity in cannabinoid CB1 receptor knockout mice. *J Psychopharmacol* (2010).
71. Rohrich, J. et al. Concentrations of Delta9-tetrahydrocannabinol and 11-Nor-9-carboxytetrahydrocannabinol in blood and urine after passive exposure to cannabis smoke in a coffee shop. *J Anal Toxicol* **34**, 196-203 (2010).
72. Izzo, A. A. & Sharkey, K. A. Cannabinoids and the gut: new developments and emerging concepts. *Pharmacol Ther* **126**, 21-38 (2010).
73. Rodgers, R. J., Holch, P. & Tallett, A. J. Behavioural Satiety Sequence (BSS): Separating wheat from chaff in the behavioural pharmacology of appetite. *Pharmacol Biochem Behav* (2010).
74. Massa, F. et al. Alterations in the hippocampal endocannabinoid system in diet-induced obese mice. *J Neurosci* **30**, 6273-6281 (2010).
75. Orio, L. et al. Additive effects of cannabinoid CB1 receptors blockade and cholecystokinin on feeding inhibition. *Pharmacol Biochem Behav* (2010).
76. Guggenhuber, S., Monory, K., Lutz, B. & Klugmann, M. AAV Vector-Mediated Overexpression of CB1 Cannabinoid Receptor in Pyramidal Neurons of the Hippocampus Protects against Seizure-Induced Excitotoxicity. *PLoS One* **5**, e15707 (2010).
77. Nogueiras, R. et al. The endocannabinoid system: role in glucose and energy metabolism. *Pharmacol Res* **60**, 93-98 (2009).
78. Garcia-Gutierrez, M. S. & Manzanares, J. The cannabinoid CB1 receptor is involved in the anxiolytic, sedative and amnesic actions of benzodiazepines. *J Psychopharmacol* (2009).
79. Zoerner, A. A. et al. Targeted stable-isotope dilution GC-MS/MS analysis of the endocannabinoid anandamide and other fatty acid ethanol amides in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci* (2009).
80. Borrelli, F. & Izzo, A. A. Role of acylethanolamides in the gastrointestinal tract with special reference to food intake and energy balance. *Best Pract Res Clin Endocrinol Metab* **23**, 33-49 (2009).
81. Sugiura, T. Physiological roles of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. *Biofactors* **35**, 88-97 (2009).
82. Chu, K. M. et al. Olvanil: A non-pungent trpv1 activator has anti-emetic properties in the ferret. *Neuropharmacology* (2009).
83. van den Pol, A. N. et al. Neuromedin B and gastrin-releasing peptide excite arcuate nucleus neuropeptide Y neurons in a novel transgenic mouse expressing strong Renilla green fluorescent protein in NPY neurons. *J Neurosci* **29**, 4622-4639 (2009).
84. Perez-Rial, S. et al. Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. *Neurobiol Aging* (2009).
85. Dockray, G. J. Cholecystokinin and gut-brain signalling. *Regul Pept* (2009).
86. Moreira, F. A., Grieb, M. & Lutz, B. Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression.

- Best Pract Res Clin Endocrinol Metab* **23**, 133-144 (2009).
87. Femenia, T., Garcia-Gutierrez, M. S. & Manzanares, J. CB1 Receptor Blockade Decreases Ethanol Intake and Associated Neurochemical Changes in Fawn-Hooded Rats. *Alcohol Clin Exp Res* (2009).
 88. Borrelli, F. et al. Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant *Cannabis sativa*, is protective in a murine model of colitis. *J Mol Med* (2009).
 89. Caraceni, P. et al. Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischemia-reperfusion injury complicated by endotoxemia. *Gut* (2009).
 90. Scheen, A. J., Paquot, N. & Van Gaal, L. F. [CB1 receptor antagonism and glucose metabolism: role of rimonabant in type 2 diabetes]. *Rev Med Suisse* **4**, 1812-1817 (2008).
 91. Viso, A., Cisneros, J. A. & Ortega-Gutierrez, S. The medicinal chemistry of agents targeting monoacylglycerol lipase. *Curr Top Med Chem* **8**, 231-246 (2008).
 92. Cluny, N. L., Keenan, C. M., Lutz, B., Piomelli, D. & Sharkey, K. A. The identification of peroxisome proliferator-activated receptor alpha-independent effects of oleoylethanolamide on intestinal transit in mice. *Neurogastroenterol Motil* (2008).
 93. Moreira, F. A. & Lutz, B. The endocannabinoid system: emotion, learning and addiction. *Addict Biol* (2008).
 94. Madsen, A. N. et al. Rimonabant induced anorexia in rodents is not mediated by vagal or sympathetic gut afferents. *Neurosci Lett* (2008).
 95. Lott, S. et al. Reference measurement procedure for Delta9-tetrahydrocannabinol in serum. *Anal Bioanal Chem* (2008).
 96. Moreira, F. A., Kaiser, N., Monory, K. & Lutz, B. Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. *Neuropharmacology* **54**, 141-150 (2008).
 97. Capasso, R. et al. Inhibitory effect of salvinin A, from *Salvia divinorum*, on ileitis-induced hypermotility: cross-talk between kappa-opioid and cannabinoid CB(1) receptors. *Br J Pharmacol* (2008).
 98. Chen, J. K. et al. Identification of novel endogenous cytochrome p450 arachidonate metabolites with high affinity for cannabinoid receptors. *J Biol Chem* (2008).
 99. Osei-Hyiaman, D. et al. Hepatic CB(1) receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. *J Clin Invest* (2008).
 100. Capasso, R. & Izzo, A. A. Gastrointestinal regulation of food intake: general aspects and focus on anandamide and oleoylethanolamide. *J Neuroendocrinol* **20 Suppl 1**, 39-46 (2008).
 101. Smid, S. D. GASTROINTESTINAL ENDOCANNABINOID SYSTEM: MULTIFACETED ROLES IN THE HEALTHY AND INFLAMED INTESTINE. *Clin Exp Pharmacol Physiol* (2008).
 102. Chhatwal, J. P. et al. Functional Interactions between Endocannabinoid and CCK Neurotransmitter Systems May Be Critical for Extinction Learning. *Neuropsychopharmacology* (2008).
 103. Muller, H. D., Sommer, C., Schwab, S., Schabitz, W. R. & Schomacher, M.

- Endocannabinoids mediate neuroprotection after transient focal cerebral ischemia. *Brain Res* (2008).
104. Izzo, A. A. & Camilleri, M. Emerging Role of Cannabinoids in Gastrointestinal and Liver Diseases: Basic and Clinical Aspects. *Gut* (2008).
 105. Rubio, M. et al. Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB(1) receptor in different brain areas. *Drug Alcohol Depend* (2008).
 106. Steiner, M. A., Marsicano, G., Wotjak, C. T. & Lutz, B. Conditional cannabinoid receptor type 1 mutants reveal neuron subpopulation-specific effects on behavioral and neuroendocrine stress responses. *Psychoneuroendocrinology* (2008).
 107. Woelkart, K., Salo-Ahen, O. M. & Bauer, R. CB receptor ligands from plants. *Curr Top Med Chem* **8**, 173-186 (2008).
 108. Aviello, G., Romano, B. & Izzo, A. A. Cannabinoids and gastrointestinal motility: animal and human studies. *Eur Rev Med Pharmacol Sci* **12 Suppl 1**, 81-93 (2008).
 109. Alvarado, M. et al. Antiobesity designed multiple ligands: Synthesis of pyrazole fatty acid amides and evaluation as hypophagic agents. *Bioorg Med Chem* (2008).
 110. Storr, M. A. & Sharkey, K. A. The endocannabinoid system and gut-brain signalling. *Curr Opin Pharmacol* **7**, 575-582 (2007).
 111. Lutz, B. The endocannabinoid system and extinction learning. *Mol Neurobiol* **36**, 92-101 (2007).
 112. Izzo, A. A. The cannabinoid CB(2) receptor: a good friend in the gut. *Neurogastroenterol Motil* **19**, 704-708 (2007).
 113. Armstrong, H. E. et al. Substituted acyclic sulfonamides as human cannabinoid-1 receptor inverse agonists. *Bioorg Med Chem Lett* **17**, 2184-2187 (2007).
 114. Cisneros, J. A. et al. Structure-Activity Relationship of a Series of Inhibitors of Monoacylglycerol Hydrolysis-Comparison with Effects upon Fatty Acid Amide Hydrolase. *J Med Chem* **50**, 5012-5023 (2007).
 115. Moreira, F. A. Serotonin, the prefrontal cortex, and the antidepressant-like effect of cannabinoids. *J Neurosci* **27**, 13369-13370 (2007).
 116. Van Gaal, L. Reducing cardiometabolic risk through selective antagonism of CB1 receptors. *Clin Cornerstone* **8 Suppl 6**, S24-S29 (2007).
 117. Rousseaux, C. et al. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. *Nat Med* **13**, 35-37 (2007).
 118. Steiner, M. A. et al. Impaired cannabinoid receptor type 1 signaling interferes with stress-coping behavior in mice. *Pharmacogenomics J* (2007).
 119. Haring, M., Marsicano, G., Lutz, B. & Monory, K. Identification of the cannabinoid receptor type 1 in serotonergic cells of raphe nuclei in mice. *Neuroscience S* (2007).
 120. Monory, K. et al. Genetic dissection of behavioural and autonomic effects of Delta(9)-tetrahydrocannabinol in mice. *PLoS Biol* **5**, e269 (2007).
 121. Lambert, D. M. & Muccioli, G. G. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players. *Curr Opin Clin Nutr Metab Care* **10**, 735-744 (2007).
 122. Fischbach, T., Greffrath, W., Nawrath, H. & Treede, R. D. Effects of anandamide and noxious heat on intracellular calcium concentration in nociceptive DRG neurons of rat. *J Neurophysiol* (2007).
 123. Gutierrez, T., Farthing, J. N., Zvonok, A. M., Makriyannis, A. & Hohmann, A. G. Activation of peripheral cannabinoid CB(1) and CB(2) receptors suppresses the

- maintenance of inflammatory nociception: a comparative analysis. *Br J Pharmacol S* **150**, 153-163 (2007).
124. Waku, K. [Endogenous cannabinoid receptor ligands--anandamide and 2-arachidonoylglycerol]. *Yakugaku Zasshi* **126**, 67-81 (2006).
 125. Mestre, L. et al. [Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis.]. *Rev Neurol* **43**, 541-548 (2006).
 126. Monory, K. et al. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. *Neuron* **51**, 455-466 (2006).
 127. Pagotto, U., Marsicano, G., Cota, D., Lutz, B. & Pasquali, R. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. *Endocr Rev* **27**, 73-100 (2006).
 128. Cota, D. et al. REQUIREMENT OF CANNABINOID RECEPTOR TYPE 1 FOR THE BASAL MODULATION OF HYPOTHALAMIC-PITUITARY-ADRENAL AXIS FUNCTION. *Endocrinology S* (2006).
 129. Sommer, C. et al. Neuroprotective cannabinoid receptor antagonist SR141716A prevents downregulation of excitotoxic NMDA receptors in the ischemic penumbra. *Acta Neuropathol (Berl)* (2006).
 130. Marsicano, G. & Lutz, B. Neuromodulatory functions of the endocannabinoid system. *J Endocrinol Invest* **29**, 27-46 (2006).
 131. Guagnini, F. et al. Neural contractions in colonic strips from patients with diverticular disease: role of endocannabinoids and substance P. *Gut* **55**, 946-953 (2006).
 132. Carai, M. A. et al. Investigation on the relationship between cannabinoid CB1 and opioid receptors in gastrointestinal motility in mice. *Br J Pharmacol* **148**, 1043-1050 (2006).
 133. Suplita, R. L., Gutierrez, T., Fegley, D., Piomelli, D. & Hohmann, A. G. Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. *Neuropharmacology* **50**, 372-379 (2006).
 134. Massa, F. & Monory, K. Endocannabinoids and the gastrointestinal tract. *J Endocrinol Invest* **29**, 47-57 (2006).
 135. Binzen, U. et al. Co-expression of the voltage-gated potassium channel Kv1.4 with transient receptor potential channels (TRPV1 and TRPV2) and the cannabinoid receptor CB1 in rat dorsal root ganglion neurons. *Neuroscience* **142**, 527-539 (2006).
 136. Sugiura, T., Kishimoto, S., Oka, S. & Gokoh, M. Biochemistry, pharmacology and physiology of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. *Prog Lipid Res S* **45**, 405-446 (2006).
 137. Ortega-Gutierrez, S. Therapeutic perspectives of inhibitors of endocannabinoid degradation. *Curr Drug Targets CNS Neurol Disord* **4**, 697-707 (2005).
 138. Patsos, H. A. et al. The endogenous cannabinoid, anandamide, induces cell death in colorectal carcinoma cells: a possible role for cyclooxygenase 2. *Gut* **54**, 1741-1750 (2005).
 139. Massa, F., Storr, M. & Lutz, B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. *J Mol Med* **83**, 944-954 (2005).
 140. Lopez-Rodriguez, M. L., Viso, A., Ortega-Gutierrez, S. & Diaz-Laviada, I. Involvement of cannabinoids in cellular proliferation. *Mini Rev Med Chem* **5**, 97-

- 106 (2005).
141. Suplita, R. L., Farthing, J. N., Gutierrez, T. & Hohmann, A. G. Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsolateral periaqueductal gray and rostral ventromedial medulla. *Neuropharmacology* **49**, 1201-1209 (2005).
 142. Capasso, R. et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. *Gastroenterology* **129**, 941-951 (2005).
 143. Gabbay, E., Avraham, Y., Ilan, Y., Israeli, E. & Berry, E. M. Endocannabinoids and liver disease--review. *Liver Int* **25**, 921-926 (2005).
 144. de Lago, E. et al. Effect of repeated systemic administration of selective inhibitors of endocannabinoid inactivation on rat brain endocannabinoid levels. *Biochem Pharmacol* **70**, 446-452 (2005).
 145. Ortega-Gutierrez, S., Molina-Holgado, E. & Guaza, C. Effect of anandamide uptake inhibition in the production of nitric oxide and in the release of cytokines in astrocyte cultures. *Glia* **52**, 163-168 (2005).
 146. Ortega-Gutierrez, S. et al. Activation of the endocannabinoid system as therapeutic approach in a murine model of multiple sclerosis. *FASEB J* **19**, 1338-1340 (2005).
 147. Desreumaux, P., Thuru, X. & Philippe, D. [Control of secretory diarrhea and colorectal cancer growth by cannabinoids in the gut]. *Gastroenterol Clin Biol* **28**, 97 (2004).
 148. Golech, S. A. et al. Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. *Brain Res Mol Brain Res* **132**, 87-92 (2004).
 149. Vaney, C. et al. Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study. *Mult Scler* **10**, 417-424 (2004).
 150. Ortega-Gutierrez, S., Hawkins, E. G., Viso, A., Lopez-Rodriguez, M. L. & Cravatt, B. F. Comparison of anandamide transport in FAAH wild-type and knockout neurons: evidence for contributions by both FAAH and the CB1 receptor to anandamide uptake. *Biochemistry* **43**, 8184-8190 (2004).
 151. Ruiz-Llorrente, L. et al. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. *Br J Pharmacol* **141**, 457-467 (2004).
 152. Allen, J. H., de Moore, G. M., Heddle, R. & Twartz, J. C. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse. *Gut* **53**, 1566-1570 (2004).
 153. Croci, T., Landi, M., Galzin, A. M. & Marini, P. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. *Br J Pharmacol* **140**, 115-122 (2003).
 154. Fowler, C. J. et al. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. *J Enzyme Inhib Med Chem* **18**, 225-231 (2003).
 155. Gutierrez, T. et al. Effects of neurotoxic destruction of descending noradrenergic pathways on cannabinoid antinociception in models of acute and tonic nociception. *Brain Res* **987**, 176-185 (2003).

156. Lopez-Rodriguez, M. L. et al. Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: comparison with effects on fatty acid amidohydrolase. *J Med Chem* **46**, 1512-1522 (2003).
157. Lopez-Rodriguez, M. L. et al. Design, synthesis and biological evaluation of new endocannabinoid transporter inhibitors. *Eur J Med Chem* **38**, 403-412 (2003).
158. Marsicano, G. et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. *Science* **302**, 84-88 (2003).
159. Vigna, S. R. Cannabinoids and the gut. *Gastroenterology* **125**, 973-975 (2003).
160. Partosoedarso, E. R., Abrahams, T. P., Scullion, R. T., Moerschbaecher, J. M. & Hornby, P. J. Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. *J Physiol* **550**, 149-158 (2003).
161. de Lago, E. et al. UCM707, a potent and selective inhibitor of endocannabinoid uptake, potentiates hypokinetic and antinociceptive effects of anandamide. *Eur J Pharmacol* **449**, 99-103 (2002).
162. Bartho, L., Benko, R., Lazar, Z., Illenyi, L. & Horvath, O. P. Nitric oxide is involved in the relaxant effect of capsaicin in the human sigmoid colon circular muscle. *Naunyn Schmiedebergs Arch Pharmacol* **366**, 496-500 (2002).
163. Manara, L. et al. Functional assessment of neuronal cannabinoid receptors in the muscular layers of human ileum and colon. *Dig Liver Dis* **34**, 262-269 (2002).
164. Pinto, L., Capasso, R., Di Carlo, G. & Izzo, A. A. Endocannabinoids and the gut. *Prostaglandins Leukot Essent Fatty Acids* **66**, 333-341 (2002).
165. Sugiura, T. & Waku, K. Cannabinoid receptors and their endogenous ligands. *J Biochem (Tokyo)* **132**, 7-12 (2002).
166. Izzo, A. A., Mascolo, N. & Capasso, F. The gastrointestinal pharmacology of cannabinoids. *Curr Opin Pharmacol* **1**, 597-603 (2001).
167. Lopez-Rodriguez, M. L. et al. Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors. *J Med Chem* **44**, 4505-4508 (2001).
168. Pertwee, R. G. Cannabinoids and the gastrointestinal tract. *Gut* **48**, 859-867 (2001).
169. Izzo, A. A. et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. *Br J Pharmacol* **134**, 563-570 (2001).
170. Kulkarni-Narla, A. & Brown, D. R. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. *Cell Tissue Res* **302**, 73-80 (2000).
171. Izzo, A. A., Mascolo, N. & Capasso, F. Forgotten target for marijuana: the endocannabinoid system in the gut. *Trends Pharmacol Sci* **21**, 372-373 (2000).
172. Sugiura, T. & Waku, K. 2-Arachidonoylglycerol and the cannabinoid receptors. *Chem Phys Lipids* **108**, 89-106 (2000).
173. Mockel, M., Kampf, D., Lobeck, H. & Frei, U. Severe panarteritis associated with drug abuse. *Intensive Care Med* **25**, 113-117 (1999).
174. Croci, T. et al. In vitro functional evidence of neuronal cannabinoid CB1 receptors in human ileum. *Br J Pharmacol* **125**, 1393-1395 (1998).
175. Ben-Shabat, S. et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. *Eur J Pharmacol* **353**, 23-31 (1998).

176. Griffin, G. et al. Evidence for the presence of CB2-like cannabinoid receptors on peripheral nerve terminals. *Eur J Pharmacol* **339**, 53-61 (1997).
177. Eskridge, K. D. & Guthrie, S. K. Clinical issues associated with urine testing of substances of abuse. *Pharmacotherapy* **17**, 497-510 (1997).
178. Mechoulam, R. et al. Endogenous cannabinoid ligands--chemical and biological studies. *J Lipid Mediat Cell Signal* **14**, 45-49 (1996).
179. Mechoulam, R. et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. *Biochem Pharmacol* **50**, 83-90 (1995).
180. Malbrain, M. L. et al. A massive, near-fatal cocaine intoxication in a body-stuffer. Case report and review of the literature. *Acta Clin Belg* **49**, 12-18 (1994).
181. Mattes, R. D., Shaw, L. M., Edling-Owens, J., Engelman, K. & Elsohly, M. A. Bypassing the first-pass effect for the therapeutic use of cannabinoids. *Pharmacol Biochem Behav* **44**, 745-747 (1993).
182. Shook, J. E. & Burks, T. F. Psychoactive cannabinoids reduce gastrointestinal propulsion and motility in rodents. *J Pharmacol Exp Ther* **249**, 444-449 (1989).
183. Smith, D. E., Gutgesell, M. E., Schwartz, R. H., Thorne, M. M. & Bogema, S. Federal guidelines for marijuana screening should have lower cutoff levels. A comparison of results from immunoassays and gas chromatography-mass spectrometry. *Arch Pathol Lab Med* **113**, 1299-1300 (1989).
184. Stapleton, J. M., Guthrie, S. & Linnoila, M. Effects of alcohol and other psychotropic drugs on eye movements: relevance to traffic safety. *J Stud Alcohol* **47**, 426-432 (1986).
185. Malagelada, J. R. Potential pharmacological approaches to management of gut motility disorders. *Scand J Gastroenterol Suppl* **96**, 111-126 (1984).
186. Valentine, J. L. et al. High-pressure liquid chromatographic--mass spectrometric determination of delta9-tetrahydrocannabinol in human plasma following marijuana smoking. *J Pharm Sci* **66**, 1263-1266 (1977).
187. Valentine, J. L. et al. HPLC-MS determination of delta9-tetrahydrocannabinol in human body samples. *NIDA Res Monogr* **7**, 96-106 (1976).